Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metreleptin in partial lipodystrophy
2022-501799-24-00Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in partial lipodystrophy comparing Metreleptin with Placebo (2 arms). Primary endpoints: Change from baseline to Month 6 in glycated hemoglobin and Percent change from baseline to Month 6 in fasting triglycerides. Started Mar 2024; status: completed.
02
Drugs
metreleptin
03
Conditions
partial lipodystrophy
Beyond the preview
Go deeper on 2022-501799-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501799-24-00.